The search textbox has an autosuggest feature. When you enter three or more characters,
a list of up to 10 suggestions will popup under the textbox. Use the arrow keys
to move through the suggestions. To select a suggestion, hit the enter key. Using
the escape key closes the listbox and puts you back at the textbox. The radio buttons
allow you to toggle between having all search items start with or contain the text
you entered in the search box.
extended release bupivacaine hydrochloride resorbable matrix formulation
An extended release (ER) injectable formulation composed of the hydrochloride salt form of bupivacaine, an amide-type, long-acting local anesthetic, in a resorbable sucrose acetate isobutyrate-based matrix, with analgesic activity. Following administration in or around a specific site, ER bupivacaine is released from the matrix over an extended period of time. Upon release, bupivacaine reversibly binds to specific voltage-gated sodium ion channels in the neuronal membrane, resulting in a decrease in the voltage-dependent membrane permeability to sodium ions, membrane destabilization, and depolarization inhibition thus disrupting nerve impulse conduction. This eventually leads to a reversible loss of sensation. This formulation may provide pain relief up to 72 hours. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
| Synonyms: | | ER bupivacaine HCl extended release bupivacaine hydrochloride SABER-bupivacaine chloride sustained release bupivacaine hydrochloride | |
| |||
| US brand name: | | Posidur | |
| |||
